Patents by Inventor Anne-Sophie Bessis

Anne-Sophie Bessis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alkynyl derivatives as modulators of metabotropic glutamate receptors
    Patent number: 8883826
    Abstract: The present invention relates to novel compounds of formula I wherein W, n, X and W? are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: November 11, 2014
    Assignee: Addex Pharma SA
    Inventors: Anne-Sophie Bessis, Christelle Bolea, Beatrice Bonnet, Mark Epping-Jordan, Nicolas Poirier, Sonia-Maria Poli, Jean-Philippe Rocher, Yves Thollon
  • NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
    Publication number: 20120277237
    Abstract: The present invention relates to novel compounds of formula I wherein W, n, X and W? are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Application
    Filed: December 20, 2011
    Publication date: November 1, 2012
    Applicant: Addex Pharma SA
    Inventors: Anne-Sophie Bessis, Christelle Bolea, Beatrice Bonnet, Mark Epping-Jordan, Nicolas Poirier, Sonia-Maria Poli, Jean-Philippe Rocher, Yves Thollon
  • Allosteric modulators of metabotropic glutamate receptors
    Patent number: 8163775
    Abstract: The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: April 24, 2012
    Assignee: Addex Pharma SA
    Inventors: Anne-Sophie Bessis, Beatrice Bonnet, Emmanuel Le Poul, Jean-Philippe Rocher, Mark Epping-Jordan
  • ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
    Publication number: 20120022108
    Abstract: The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Application
    Filed: September 30, 2011
    Publication date: January 26, 2012
    Applicant: Addex Pharma SA
    Inventors: Anne-Sophie Bessis, Beatrice Bonnet, Emmanuel Le Poul, Jean-Philippe Rocher, Mark Eppig-Jordan
  • Alkynyl derivatives as modulators of metatropic glutamate receptors
    Patent number: 8101637
    Abstract: The present invention relates to novel compounds of formula (I) wherein W, n, X and W? are defined in the description; invention compounds are modulators of metabotropic glutamate receptors-subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: January 24, 2012
    Assignee: Addex Pharma SA
    Inventors: Anne-Sophie Bessis, Christelle Bolea, Béatrice Bonnet, Mark Epping-Jordan, Nicholas Poirier, Sonia-Maria Poli, Jean-Philippe Rocher, Yves Thollon
  • Allosteric modulators of metabotropic glutamate receptors
    Patent number: 8030331
    Abstract: The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: October 4, 2011
    Assignee: Addex Pharma SA
    Inventors: Anne-Sophie Bessis, Beatrice Bonnet, Emmanuel Le Poul, Jean-Philippe Rocher, Mark Epping-Jordan
  • ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
    Publication number: 20110112143
    Abstract: The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Application
    Filed: October 6, 2010
    Publication date: May 12, 2011
    Applicant: Addex Pharma SA
    Inventors: Anne-Sophie Bessis, Beatrice Bonnet, Emmanuel Le Poul, Jean-Philippe Rocher, Mark Epping-Jordan
  • Allosteric modulators of metabotropic glutamate receptors
    Patent number: 7834035
    Abstract: The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: November 16, 2010
    Assignee: Addex Pharma SA
    Inventors: Anne-Sophie Bessis, Beatrice Bonnet, Emmanuel Le Poul, Jean-Philippe Rocher, Mark Epping-Jordan
  • NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS
    Publication number: 20090124625
    Abstract: The present invention relates to novel compounds of formula (I) wherein W, n, X and W? are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Application
    Filed: June 17, 2005
    Publication date: May 14, 2009
    Applicant: Addex Pharmaceuticals SA
    Inventors: Anne-Sophie Bessis, Christelle Bolea, Beatrice Bonnet, Mark Epping-Jordan, Nicolas Poirier, Sonia-Maria Poli, Jean-Philippe Rocher, Yves Thollon
  • Novel aminopyridine derivatives as mGluR5 antagonists
    Publication number: 20080004316
    Abstract: The invention relates to novel aminopyridine derivatives of formula (I) wherein R1 is methyl an R4 and amino group —NR6R7 and R5 forms an arylalkynyl- or heteroarylalkynyl-group. The compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Application
    Filed: March 13, 2007
    Publication date: January 3, 2008
    Applicant: Addex Pharmaceuticals SA
    Inventors: Christelle Bolea, Vincent Mutel, Jean-Philippe Rocher, Anne-Sophie Bessis, Emmanuel Le Poul
  • Allosteric Modulators of Metabotropic Glutamate Receptors
    Publication number: 20070219187
    Abstract: The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Application
    Filed: November 4, 2004
    Publication date: September 20, 2007
    Inventors: Anne-Sophie Bessis, Beatrice Bonnet, Emmanuel Le Poul, Jean-Philippe Rocher, Mark Epping-Jordan
  • Aminopyridine derivatives as mGluR5 antagonists
    Patent number: 7205411
    Abstract: The invention relates to novel aminopyridine derivatives of formula (I) wherein R1 is methyl an R4 and amino group —NR6R7 and R5 forms an arylalkynyl- or heteroarylalkynyl-group.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: April 17, 2007
    Assignee: Addex Pharmaceuticals SA
    Inventors: Christelle Bolea, Vincent Mutel, Jean-Philippe Rocher, Anne-Sophie Bessis, Emmanuel Le Poul
  • Novel aminopyridine derivatives as mGluR5 antagonists
    Publication number: 20060030601
    Abstract: The invention relates to novel aminopyridine derivatives of formula (I) wherein R1 is methyl an R4 and amino group —NR6R7 and R5 forms an arylalkynyl- or heteroarylalkynyl-group. The compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.
    Type: Application
    Filed: September 2, 2005
    Publication date: February 9, 2006
    Applicant: Addex Pharmaceuticals SA
    Inventors: Christelle Bolea, Vincent Mutel, Jean-Philippe Rocher, Anne-Sophie Bessis, Emmanuel Le Poul